Sign up for the QMED & MD+DI Daily newsletter.
The Wall Street Journal reports that there is turmoil in discussions to replace FDA Commissioner Andrew von Eschenbach. Although von Eschenbach has not yet announced his plans, his departure is expected soon.In the meantime, Representative Bart Stupak (D-MI), has asked Obama to avoid naming a replacement, in particular anyone associated with current FDA leadership. In a letter Wednesday to Mr.
December 6, 2008
1 Min Read
Obama, Stupak wrote, "I would encourage you not to appoint any current senior FDA employee as Commissioner or Interim Commissioner of the FDA," reports the journal.He added, "Current senior FDA employees are too close with the industries they regulate, creating a question of who they are working for." He called for a "complete change in the FDA's leadership." The letter doesn't name any officials.Janet Woodcock's name has been in conversations as a possible interim or permanent FDA chief. Other nonFDA names being heard include Joshua Sharfstein, head of the Baltimore Health Department, and Steven Nissen, chief of cardiovascular medicine at the Cleveland Clinic.
You May Also Like
FDA Urges Independent Verification of Third-Party Testing DataFeb 21, 2024|2 Min Read
3M’s Healthcare Business to Stand on Its Own in AprilFeb 21, 2024|1 Min Read
BioSig Cuts a Substantial Number of PositionsFeb 20, 2024|2 Min Read
Philips BrightView Imaging System Hit with Class I RecallFeb 20, 2024|2 Min Read